What is Wegovy?
Wegovy is a GLP-1 receptor agonist weight-management injection whose active ingredient is semaglutide. At Seye Clinic we offer five dose strengths from 0.25mg to 2.4mg, given as a once-weekly subcutaneous injection that helps control appetite and support weight loss. It is administered with a pen-type injector, without surgery or incisions, so it fits easily into daily life.
How it works
Semaglutide, the active ingredient in Wegovy, mimics GLP-1, a hormone your gut releases after eating. It acts on the appetite centers in the brain to prolong the feeling of fullness and slows the rate at which the stomach empties, so you naturally eat less. It also helps regulate blood sugar and insulin secretion, supporting overall metabolism. Treatment starts at a low 0.25mg dose and is increased step by step roughly every 4 weeks to 0.5mg, 1.0mg, 1.7mg and 2.4mg; this gradual 16-week escalation is a safeguard that reduces gastrointestinal side effects such as nausea.
Key benefits
- In large clinical trials, about 68 weeks of treatment produced an average weight loss of roughly 15% of baseline body weight (14.9–17.4%); results vary by individual.
- Helps improve eating habits such as overeating and frequent snacking by regulating appetite and fullness.
- A once-weekly schedule means less daily burden than daily injections.
- Alongside weight loss, improvements in metabolic markers such as blood sugar and lipids may be expected.
- Performed as a simple pen-type self-injection with no incision or surgery.
Recommended for
- Those who repeatedly give up on diets because appetite is hard to control
- Those who feel diet and exercise alone are not enough for weight loss
- Those who prefer a once-weekly option over daily injections
- Those who want to manage blood sugar and metabolism along with weight
- Those who want to begin obesity treatment safely under medical supervision
Wegovy at Seye Clinic
At Seye Clinic, the first consultation reviews your weight, health status and medical history before we set an individualized escalation plan starting from the low 0.25mg dose. We screen in advance for conditions where treatment is not advised, such as a history of medullary thyroid cancer or pregnancy, and we help manage nausea and digestive symptoms that can appear during dose escalation. All consultation fees are included in the treatment price, and we prioritize safety over aggressive weight loss.